GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley Sells 922 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 922 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $94.72, for a total value of $87,331.84. Following the completion of the transaction, the chief financial officer now owns 5,446 shares in the company, valued at $515,845.12. This represents a 14.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total value of $108,737.20.
• On Monday, December 16th, Kevin Feeley sold 3,728 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $286,124.00.

GeneDx Stock Performance

NASDAQ:WGS opened at $92.08 on Thursday. The firm has a market capitalization of $2.58 billion, a PE ratio of -46.98 and a beta of 1.90. The business’s fifty day moving average price is $84.02 and its 200 day moving average price is $68.85. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. GeneDx Holdings Corp. has a 12 month low of $7.72 and a 12 month high of $115.60.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. On average, sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several large investors have recently bought and sold shares of WGS. Principal Financial Group Inc. acquired a new position in GeneDx in the third quarter valued at $604,000. Chartwell Investment Partners LLC acquired a new position in GeneDx in the third quarter valued at $1,722,000. Lisanti Capital Growth LLC acquired a new position in GeneDx in the third quarter valued at $1,554,000. GSA Capital Partners LLP acquired a new position in GeneDx in the third quarter valued at $322,000. Finally, Royce & Associates LP acquired a new position in GeneDx in the third quarter valued at $1,201,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Analyst Upgrades and Downgrades

WGS has been the topic of a number of recent research reports. TD Cowen upped their price objective on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research report on Tuesday, January 7th. The Goldman Sachs Group upped their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and an average target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.